




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 261/12, 231/20, 213/64, A61K 31/42, 31/415, 31/44	A1	(11) International Publication Number: WO 95/17392 (43) International Publication Date: 29 June 1995 (29.06.95)
(21) International Application Number: PCT/GB94/02783 (22) International Filing Date: 21 December 1994 (21.12.94) (30) Priority Data: 9326600.5 22 December 1993 (22.12.93) GB (71) Applicant: CELLTECH THERAPEUTICS LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB). (72) Inventors: WARRELOW, Graham, John; Oakside, 4 Wieland Road, Northwood, Middlesex HA6 3QU (GB). BOYD, Ewan, Campbell; 30 Ledi Avenue, Tullibody, Clacks FK10 2RZ (GB). ALEXANDER, Rikki, Peter; 14 Carrington Road, High Wycombe, Bucks HP12 3HY (GB). EATON, Michael, Anthony, William; Nethercote, Chinnor Road, Aston Rowant, Watlington, Oxon OX9 5SH (GB). (74) Agent: SKAILES, Humphrey, John; Frank B Dehn & Co, Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).		(81) Designated States: JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: TRISUBSTITUTED PHENYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHOSPHODIESTERASE (TYPE IV) INHIBITOR <div style="text-align: center;">  </div> (57) Abstract <p>Compounds of general formula (1), wherein Y is a halogen atom or a group -OR¹ where R¹ is an optionally substituted alkyl group; X is -O-, -S- or -N(R⁸)-, where R⁸ is a hydrogen atom or an alkyl group; R² is an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group; R³ is a hydrogen or halogen atom or an -OR⁹ group, where R⁹ is a hydrogen atom or an optionally substituted alkyl, alkenyl, alkoxyalkyl, or alkanoyl group, or a formyl, carboxamido or thiocarboxamido group; R⁴ is a group -(CH₂)_nAr, where Ar is a monocyclic or bicyclic aryl group optionally containing one or more heteratoms selected from oxygen, sulphur or nitrogen atoms and n is zero or an integer 1, 2 or 3; R⁵ is a C₃₋₉carbocyclic ketone optionally containing one or more heteratoms selected from oxygen, sulphur or nitrogen atoms; R⁶ is a hydrogen atom or an optionally substituted alkyl group; R⁷ is a hydrogen atom or an optionally substituted alkyl group; and the salts, solvates, hydrates and N-oxides thereof. Compounds according to the invention are potent and selective phosphodiesterase type IV inhibitors and are useful in the prophylaxis and treatment of diseases such as asthma where an unwanted inflammatory response or muscular spasm is present.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

TRISUBSTITUTED PHENYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR
USE AS PHOSPHODIESTERASE (TYPE IV) INHIBITOR

- 5 This invention relates to a novel series of tri-substituted phenyl derivatives,
to processes for their preparation, to pharmaceutical compositions
containing them, and to their use in medicine.

10 Many hormones and neurotransmitters modulate tissue function by
elevating intra-cellular levels of adenosine 3', 5'-cyclic monophosphate
(cAMP). The cellular levels of cAMP are regulated by mechanisms which
control synthesis and breakdown. The synthesis of cAMP is controlled by
15 adenylyl cyclase which may be directly activated by agents such as
forskolin or indirectly activated by the binding of specific agonists to cell
surface receptors which are coupled to adenylyl cyclase. The breakdown
of cAMP is controlled by a family of phosphodiesterase (PDE)
isoenzymes, which also control the breakdown of guanosine 3',5'-cyclic
monophosphate (cGMP). To date, seven members of the family have
20 been described (PDE I-VII) the distribution of which varies from tissue to
tissue. This suggests that specific inhibitors of PDE isoenzymes could
achieve differential elevation of cAMP in different tissues, [for reviews of
PDE distribution, structure, function and regulation, see Beavo &
Reifsnnyder (1990) TIPS, 11: 150-155 and Nicholson et al (1991) TIPS, 12:
19-27].


25 There is clear evidence that elevation of cAMP in inflammatory leukocytes
leads to inhibition of their activation. Furthermore, elevation of cAMP in
airway smooth muscle has a spasmolytic effect. In these tissues, PDE IV
plays a major role in the hydrolysis of cAMP. It can be expected,
30 therefore, that selective inhibitors of PDE IV would have therapeutic
effects in inflammatory diseases such as asthma, by achieving both anti-
inflammatory and bronchodilator effects.

35 The design of PDE IV inhibitors has met with limited success to date, in
that many of the potential PDE IV inhibitors which have been synthesised

have lacked potency and/or have been capable of inhibiting more than one type of PDE isoenzyme in a non-selective manner. Lack of a selective action has been a particular problem given the widespread role of cAMP in vivo and what is needed are potent selective PDE IV inhibitors with an inhibitory action against PDE IV and little or no action against other PDE isoenzymes.

We have now found a novel series of tri-substituted phenyl derivatives, members of which compared to known structurally similar compounds are potent inhibitors of PDE IV at concentrations at which they have little or no inhibitory action on other PDE isoenzymes. These compounds inhibit the human recombinant PDE IV enzyme and also elevate cAMP in isolated leukocytes. The compounds of the invention are therefore of use in medicine, especially in the prophylaxis and treatment of asthma.

Thus according to one aspect of the invention, we provide a compound of formula (1)



20

wherein

Y is a halogen atom or a group -OR¹ where R¹ is an optionally substituted alkyl group;

X is -O-, -S- or -N(R⁸)-, where R⁸ is a hydrogen atom or an alkyl group;

25 R² is an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group;

R³ is a hydrogen or halogen atom or an -OR⁹ group, where R⁹ is a hydrogen atom or an optionally substituted alkyl, alkenyl, alkoxyalkyl, or alkanoyl group, or a formyl, carboxamido or thiocarboxamido group;

30 R⁴ is a group -(CH₂)_nAr, where Ar is a monocyclic or bicyclic aryl group optionally containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms and n is zero or an integer 1,2 or 3;

R⁵ is a C₃₋₉carbocyclic ketone optionally containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms;

R⁶ is a hydrogen atom or an optionally substituted alkyl group;

R⁷ is a hydrogen atom or an optionally substituted alkyl group; and the
5 salts, solvates, hydrates and N-oxides thereof.

It will be appreciated that the compounds of formula (1) may have one or more chiral centres, depending on the nature of the groups R³, R⁴, R⁵, R⁶ and R⁷. Where one or more chiral centres is present, enantiomers or
10 diastereomers may exist, and the invention is to be understood to extend to all such enantiomers, diastereomers and mixtures thereof, including racemates.

In the compounds of formula (1), when Y is a halogen atom it may be for
15 example a fluorine, chlorine, bromine or iodine atom.

When Y in the compounds of formula (1) is a group -OR¹, R¹ may be, for example, an optionally substituted straight or branched alkyl group, for example, an optionally substituted C₁₋₆alkyl group, such as a methyl,
20 ethyl, n-propyl or i-propyl group. Optional substituents which may be present on R¹ groups include one or more halogen atoms, e.g. fluorine, or chlorine atoms. Particular substituted alkyl groups include for example -CH₂F, -CH₂Cl, -CHF₂, -CHCl₂, -CF₃ or -CCl₃ groups.

25 Alkyl groups represented by R², R⁶ or R⁷ in the compounds of formula (1) include optionally substituted straight or branched C₁₋₆ alkyl groups, e.g. C₁₋₃ alkyl groups such as methyl or ethyl groups. Optional substituents on these groups include one, two or three substituents selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or hydroxyl or C₁₋₆
30 alkoxy e.g. C₁₋₃ alkoxy such as methoxy or ethoxy groups.

Alkenyl groups represented by R² in the compounds of formula (1) include optionally substituted straight or branched C₂₋₆alkenyl groups such as ethenyl, propen-1-yl and 2-methylpropen-1-yl. Optional substituents
35 include those described above in relation to the groups R², R⁶ and R⁷.

When R^2 in the compounds of formula (1) is an optionally substituted cycloalkyl or cycloalkenyl group it may be for example a C_{3-8} cycloalkyl group such as a cyclobutyl, cyclopentyl or cyclohexyl group or a C_{3-8} cycloalkenyl group containing for example one or two double bonds such as a 2-cyclobuten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2,4-cyclopentadien-1-yl, 2-cyclohexen-1-yl, 3-cyclohexen-1-yl, 2,4-cyclohexadien-1-yl or 3,5-cyclohexadien-1-yl group, each cycloalkyl or cycloalkenyl group being optionally substituted by one, two or three substituents selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, straight or branched C_{1-6} alkyl e.g. C_{1-3} alkyl such as methyl or ethyl, hydroxyl or C_{1-6} alkoxy e.g. C_{1-3} alkoxy such as methoxy or ethoxy groups.

Alkyl groups represented by R^8 in compounds of formula (1) include straight or branched C_{1-6} alkyl groups, e.g. C_{1-3} alkyl groups such as methyl or ethyl groups. Thus, for example, when X in the compounds of formula (1) is $-N(R^8)-$ it may be a $-N(CH_3)-$ or $-N(CH_2CH_3)-$ group. Alternatively X may be a $-NH-$ group.

20

When the group R^3 in compounds of formula (1) is a halogen atom it may be for example a fluorine, chlorine, bromine or iodine atom.

When the group R^3 in compounds of formula (1) is an $-OR^9$ group it may be for example a hydroxyl group; or a group $-OR^9$ where R^9 is an optionally substituted straight or branched C_{1-6} alkyl group, e.g. a C_{1-3} alkyl group such as a methyl or ethyl group, a C_{2-6} alkenyl group such as an ethenyl or 2-propen-1-yl group, a C_{1-3} alkoxy C_{1-3} alkyl group such as a methoxymethyl, ethoxymethyl or ethoxyethyl group, a C_{1-6} alkanoyl, e.g. C_{1-3} alkanoyl such as acetyl group, or a formyl $[HC(O)-]$ or a carboxamido $(CONR^{11}R^{12})$ or thiocarboxamido $(CSNR^{11}R^{12})$ group, where R^{11} and R^{12} in each instance may be the same or different and is each a hydrogen atom or an optionally substituted straight or branched C_{1-6} alkyl, e.g. C_{1-3} alkyl group such as a methyl or ethyl group. Optional

25

30

substituents which may be present on such R⁹ groups include those described above in relation to the alkyl groups R², R⁶ and R⁷.

5 In the compounds of formula (1) the group R⁴ may be a group -Ar, -CH₂Ar, -(CH₂)₂Ar or -(CH₂)₃Ar.

10 Monocyclic or bicyclic aryl groups represented by the group Ar in compounds of formula (1) include for example C₆₋₁₂ optionally substituted aryl groups, for example optionally substituted phenyl, 1-or 2-naphthyl, indenyl or isoindenyl groups.

When the monocyclic or bicyclic aryl group Ar contains one or more heteroatoms it may be for example a C₁₋₉ optionally substituted heteroaryl group containing for example one, two, three or four heteroatoms selected
15 from oxygen, sulphur or nitrogen atoms. In general, Ar heteroaryl groups may be for example monocyclic or bicyclic heteroaryl groups. Monocyclic heteroaryl groups include for example five- or six-membered heteroaryl groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms.

20 Examples of heteroaryl groups represented by Ar include pyrrolyl, furyl, thienyl, imidazolyl, N-methylimidazolyl, N-ethylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl,
25 pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolyl, isoindolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolinyl, isoquinolinyl, tetrazolyl, 5,6,7,8-tetra-
30 hydroquinolinyl and 5,6,7,8-tetrahydroisoquinolinyl.

The heteroaryl group represented by Ar may be attached to the remainder of the molecule of formula (1) through any ring carbon or heteroatom as appropriate. Thus, for example, when the group Ar is a pyridyl group it
35 may be a 2-pyridyl, 3-pyridyl or 4-pyridyl group. When it is a thienyl group

it may be a 2-thienyl or 3-thienyl group, and, similarly, when it is a furyl group it may be a 2-furyl or 3-furyl group.

When in compounds of formula (1) the Ar group is a nitrogen-containing heterocycle it may be possible to form quaternary salts, for example N-alkyl quaternary salts and the invention is to be understood to extend to such salts. Thus for example when the group Ar is a pyridyl group, pyridinium salts may be formed, for example N-alkylpyridinium salts such as N-methylpyridinium.

10

The aryl or heteroaryl groups represented by Ar in compounds of formula (1) may each optionally be substituted by one, two, three or more substituents $[R^{10}]$. The substituent R^{10} may be selected from an atom or group R^{13} or $-Alk^1(R^{13})_m$ wherein R^{13} is a halogen atom, or an amino ($-NH_2$), substituted amino, nitro, cyano, hydroxyl ($-OH$), substituted hydroxyl, cycloalkoxy, formyl $[HC(O)-]$, carboxyl ($-CO_2H$), esterified carboxyl, thiol ($-SH$), substituted thiol, $-C(O)Alk^1$, $-SO_3H$, $-SO_2Alk^1$, $-SO_2NH_2$, $-SO_2NHAik^1$, $-SO_2N[Alk^1]_2$, $-CONH_2$, $-CONHAik^1$, $-CON[Alk^1]_2$, $-NHSO_2H$, $-NHSO_2Alk^1$, $-N[SO_2Alk^1]_2$, $-NHSO_2NH_2$, $-NHSO_2NHAik^1$, $-NHSO_2N[Alk^1]_2$, $-NHC(O)Alk^1$, or $-NHC(O)OAlk^1$ group; Alk^1 is a straight or branched C_{1-6} alkylene, C_{2-6} alkenylene, or C_{2-6} alkynylene chain optionally interrupted by one, two, or three $-O-$, or $-S-$ atoms or $-S(O)p-$, [where p is an integer 1 or 2] or $-N(R^8)-$ groups; and m is zero or an integer 1, 2 or 3.

25

When in the group $-Alk^1(R^{13})_m$ m is an integer 1, 2 or 3, it is to be understood that the substituent or substituents R^{13} may be present on any suitable carbon atom in $-Alk^1$. Where more than one R^{13} substituent is present these may be the same or different and may be present on the same or different carbon atom in Alk^1 . Clearly, when m is zero and no substituent R^{13} is present or when Alk^1 forms part of a group such as $-SO_2Alk^1$ the alkylene, alkenylene or alkynylene chain represented by Alk^1 becomes an alkyl, alkenyl or alkynyl group.

30

When R^{13} is a substituted amino group it may be a group $-NH[Alk^1(R^{13a})_m]$ [where Alk^1 and m are as defined above and R^{13a} is as defined above for R^{13} but is not a substituted amino, a substituted hydroxyl or a substituted thiol group] or a group $-N[Alk^1(R^{13a})_m]_2$ wherein each $-Alk^1(R^{13a})_m$ group is the same or different.

When R^{13} is a halogen atom it may be for example a fluorine, chlorine, bromine, or iodine atom.

10 When R^{13} is a cycloalkoxy group it may be for example a C_{5-7} cycloalkoxy group such as a cyclopentyloxy or cyclohexyloxy group.

When R^{13} is a substituted hydroxyl or substituted thiol group it may be a group $-OAlk^1(R^{13a})_m$ or $-SAlk^1(R^{13a})_m$ respectively, where Alk^1 , R^{13a} and m are as just defined.

Esterified carboxyl groups represented by the group R^{13} include groups of formula $-CO_2Alk^2$ wherein Alk^2 is a straight or branched, optionally substituted C_{1-8} alkyl group such as a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t-butyl group; a C_{6-12} aryl C_{1-8} alkyl group such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1-naphthylmethyl or 2-naphthylmethyl group; a C_{6-12} aryl group such as an optionally substituted phenyl, 1-naphthyl or 2-naphthyl group; a C_{6-12} aryloxy C_{1-8} alkyl group such as an optionally substituted phenyloxymethyl, phenyloxyethyl, 1-naphthyloxymethyl, or 2-naphthyloxymethyl group; an optionally substituted C_{1-8} alkanoyloxy C_{1-8} alkyl group, such as a pivaloyloxymethyl, propionyloxyethyl or propionyloxypropyl group; or a C_{6-12} aroyloxy C_{1-8} alkyl group such as an optionally substituted benzoyloxyethyl or benzoyloxypropyl group. Optional substituents present on the Alk^2 group include R^{10} substituents described above.

When Alk^1 is present in or as a substituent R^{10} it may be for example a methylene, ethylene, n-propylene, i-propylene, n-butylene, i-butylene, s-butylene, t-butylene, ethenylene, 2-propenylene, 2-butenylene, 3-butenylene, ethynylene, 2-propynylene, 2-butynylene or 3-butynylene

chain, optionally interrupted by one, two, or three -O- or -S-, atoms or -S(O)-, -S(O)₂- or -N(R⁸)- groups.

Particularly useful atoms or groups represented by R¹⁰ include fluorine,
5 chlorine, bromine or iodine atoms, or C₁₋₆alkyl, e.g. methyl or ethyl, C₁₋₆alkylamino, e.g. methylamino or ethylamino, C₁₋₆ hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, C₁₋₆alkylthiol e.g. methylthiol or ethylthiol, C₁₋₆alkoxy, e.g. methoxy or ethoxy, C₅₋₇cycloalkoxy, e.g. cyclo-pentyloxy, haloC₁₋₆alkyl, e.g. trifluoromethyl, C₁₋₆alkylamino, e.g. methylamino or
10 ethylamino, amino (-NH₂), aminoC₁₋₆alkyl, e.g. aminomethyl or aminoethyl, C₁₋₆dialkylamino, e.g. dimethylamino or diethylamino, nitro, cyano, hydroxyl (-OH), formyl [HC(O)-], carboxyl (-CO₂H), -CO₂Alk² [where Alk² is as defined above], C₁₋₆alkanoyl e.g. acetyl, thiol (-SH), thioC₁₋₆alkyl, e.g. thiomethyl or thioethyl, sulphonyl (-SO₃H), C₁₋₆alkylsulphonyl, e.g.
15 methylsulphonyl, aminosulphonyl (-SO₂NH₂), C₁₋₆alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C₁₋₆dialkylaminosulphonyl, e.g. dimethylaminosulphonyl or diethylaminosulphonyl, carbox-amido (-CONH₂), C₁₋₆alkylaminocarbonyl, e.g. methylaminocarbonyl or ethylaminocarbonyl, C₁₋₆dialkylaminocarbonyl, e.g. dimethylamino-
20 carbonyl or diethylaminocarbonyl, sulphonylamino (-NHSO₂H), C₁₋₆alkylsulphonylamino, e.g. methylsulphonylamino or ethylsulphonylamino, C₁₋₆dialkylsulphonylamino, e.g. dimethylsulphonylamino or diethylsulphonylamino, aminosulphonylamino (-NHSO₂NH₂), C₁₋₆alkylaminosulphonylamino, e.g. methylaminosulphonylamino or ethylaminosulphonylamino,
25 C₁₋₆dialkylaminosulphonylamino, e.g. dimethylaminosulphonylamino or diethylaminosulphonylamino, C₁₋₆alkanoylamino, e.g. acetylamino, C₁₋₆alkanoylamino C₁₋₆alkyl, e.g. acetylaminomethyl or C₁₋₆alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonyl-amino or t-butoxycarbonylamino groups.

30

Where desired, two R¹⁰ substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a C₂₋₆alkylenedioxy group such as ethylenedioxy.

It will be appreciated that where two or more R^{10} substituents are present, these need not necessarily be the same atoms and/or groups. The R^{10} substituents may be present at any ring carbon atom away from that attached to the rest of the molecule of formula (1). Thus, for example, in
5 phenyl groups represented by Ar any substituent may be present at the 2-, 3-, 4-, 5- or 6- positions relative to the ring carbon atom attached to the remainder of the molecule.

In the compounds of formula (1), when an ester group is present, for
10 example a group $-CO_2Alk^2$ this may advantageously be a metabolically labile ester.

The C_{3-9} carbocyclic ketone group represented by R^5 includes C_{3-9} cycloaliphatic, e.g. C_{3-9} cycloalkyl or C_{3-9} cycloalkenyl, ketones optionally
15 containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms. When a heteroatom is present, the carbocyclic group may in particular be a C_{3-5} heterocyclic ketone.

Particular examples of R^5 groups include pyrrolidone, e.g. 2-pyrrolidone,
20 thiazolidone, e.g. 4-thiazolidone, piperidone, e.g. 4-piperidone, pyridone, e.g. 2-, 3- or 4-pyridone, quinolone, e.g. 2- or 4-quinolone, isoquinolone, e.g. 1-isoquinolone, oxazolone, e.g. 4-oxazolone, pyrazolone, e.g. 5-pyrazolone, thiazolone, e.g. 4-thiazolone and isoxazolone e.g. 5-isoxazolone groups.

25 The R^5 carbocyclic ketone groups may be substituted, for example by one or more substituents R^{10} as described hereinabove. The substituent R^{10} may be present at any carbon or nitrogen atom away from that attached to the rest of the molecule of formula (1). For example, when R^5 is a
30 pyrazolone, the R^{10} substituent may be present on a carbon or nitrogen atom at the 1-, 2- or 3-position relative to the ring carbon attached to the remainder of the molecule.

The group R^5 may be attached to the remainder of the molecule of formula
35 (1) through any ring carbon or heteroatom as appropriate.

The presence of certain substituents in the compounds of formula (1) may enable salts of the compounds to be formed. Suitable salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.

Acid addition salts include hydrochlorides, hydrobromides, hydroiodides, alkylsulphonates, e.g. methanesulphonates, ethanesulphonates, or isethionates, arylsulphonates, e.g. p-toluenesulphonates, besylates or napsylates, phosphates, sulphates, hydrogen sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.


Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.

In the compounds of formula (1), the group Y is preferably an -OR¹ group, especially where R¹ is an optionally substituted ethyl group or, especially, an optionally substituted methyl group. Especially useful substituents which may be present on R¹ groups include one, two or three fluorine or chlorine atoms.

The group X in compounds of formula (1) is preferably -O-.

A particularly useful group of compounds of formula (1) has the formula (2):



(2)

where R^2 is an optionally substituted cycloalkyl group; R^3 , R^4 , R^5 , R^6 and R^7 are as defined for formula (1); and the salts, solvates, hydrates and N-oxides thereof.

In the compounds of formulae (1) or (2) R^2 is preferably an optionally substituted methyl or cyclopentyl group. In particular, R^2 is a cyclopentyl group.

10

The group R^3 in compounds of formulae (1) or (2) is preferably a hydrogen atom.

In compounds of formulae (1) or (2) the group R^6 is preferably a methyl group, or especially a hydrogen atom.

15

The group R^7 in compounds of formulae (1) or (2) is preferably a methyl group, or especially a hydrogen atom.

In one preference, R^6 and R^7 in compounds of formula (1) is each a methyl group. In another preference, one of R^6 or R^7 is a methyl group and the other is a hydrogen atom. In general, however, R^6 and R^7 is each especially a hydrogen atom.

The group R^4 in compounds of formulae (1) or (2) is preferably a $-\text{CH}_2\text{Ar}$ group, or, especially, an $-\text{Ar}$ group.

Particularly useful R^4 groups in the compounds of formulae (1) or (2) include those R^4 groups in which Ar is a monocyclic aryl group optionally containing one or more heteroatoms selected from oxygen, sulphur, or, in particular, nitrogen atoms, and optionally substituted by one, two, three or

30

more R^{10} substituents. In these compounds, when the group represented by Ar is a heteroaryl group it is preferably a nitrogen-containing monocyclic heteroaryl group, especially a six-membered nitrogen-containing heteroaryl group. Thus, in one preferred example, the group

5 R^4 may be a six-membered nitrogen-containing heteroaryl group. In another preferred example R^4 may be a monocyclic aryl group or monocyclic heteroaryl group containing an oxygen or sulphur atom. In these examples, the six-membered nitrogen-containing heteroaryl group may be an optionally substituted pyridyl, pyridazinyl, pyrimidinyl or

10 pyrazinyl group. Particular examples include optionally substituted 2-pyridyl, 3-pyridyl or, especially, 4-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl or 3-pyrazinyl. The monocyclic aryl group may be a phenyl group or a substituted phenyl group, and the monocyclic heteroaryl group containing

15 an oxygen or sulphur atom may be an optionally substituted 2-furyl, 3-furyl, 2-thienyl or 3-thienyl group.

One particularly useful group of compounds of formulae (1) or (2) is that wherein R^4 is a pyridyl or, especially, a monosubstituted pyridyl, or

20 preferably a disubstituted pyridyl group, or R^4 is a phenyl, thienyl, furyl, or substituted phenyl, thienyl or furyl group.

In this particular group of compounds and also in general in compounds of formulae (1) or (2), when R^4 is a substituted phenyl group it may be for

25 example a mono-, di- or trisubstituted phenyl group in which the substituent is an atom or group R^{10} as defined above. When the R^4 group is a monosubstituted phenyl group the substituent may be in the 2-, or preferably 3-, or especially 4-position relative to the ring carbon atom attached to the remainder of the molecule.

30 When in compounds of formulae (1) or (2) R^4 is a substituted pyridyl group it may be for example a mono- or disubstituted pyridyl group, such as a mono- or disubstituted 2-pyridyl, 3-pyridyl or especially 4-pyridyl group substituted by one or two atoms or groups R^{10} as defined above, in

35 particular one or two halogen atoms such as fluorine or chlorine atoms, or

methyl, methoxy, hydroxyl or nitro groups. Particularly useful pyridyl groups of these types are 3-monosubstituted-4-pyridyl or 3,5-disubstituted-4-pyridyl, or 2- or 4-monosubstituted-3-pyridyl or 2,4-disubstituted-3-pyridyl groups.

5

The group R⁵ in compounds of formulae (1) or (2) is preferably a C₃₋₅heterocyclic ketone, particularly an isoxazolone, pyrazolone or, especially, a pyridone group. Particularly useful groups of this type are 5-isoxalone, 5-pyrazolone or, especially, 2-pyridone groups.

10

A particularly useful group of compounds according to the invention has the formula (2) wherein R³, R⁶ and R⁷ is each a hydrogen atom and R², R⁴ and R⁵ are as defined for formula (1); and the salts, solvates, hydrates and N-oxides thereof. Compounds of this type in which R² is a cycloalkyl or substituted cycloalkyl group, especially a substituted cyclopentyl or in particular a cyclopentyl group are particularly useful. In this group of compounds, R⁴ is preferably a monocyclic aryl group, particularly a phenyl or substituted phenyl group or R⁴ is a six-membered nitrogen-containing monocyclic heteroaryl group, particularly a pyridyl or substituted pyridyl group. R⁵ is preferably a C₃₋₅heterocyclic ketone, particularly an isoxalone, particularly a 5-isoxazolonyl, a pyrazolone, particularly a 5-pyrazolonyl or, especially, a pyridone, particularly a 2-pyridone, group.

15

20

Particularly useful compounds according to the invention are:

25

(±)-3-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]-4,5-dihydro-5-isoxazolone;

(±)-3-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]-1-methyl-4,5-dihydro-5-pyrazolone;

30

(±)-3-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]-4,5-dihydro-5-pyrazolone;

(±)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]-2-pyridone; or

the resolved enantiomers thereof; and the salts, solvates, hydrates and N-oxides thereof.

35

The above specifically mentioned compounds exist in two enantiomeric forms. Each enantiomer is useful, as are mixtures of both enantiomers.

- 5 Compounds according to the invention are selective and potent inhibitors of PDE IV. The ability of the compounds to act in this way may be simply determined by the tests described in the Examples hereinafter.

- 10 The compounds according to the invention are thus of particular use in the prophylaxis and treatment of human diseases where an unwanted inflammatory response or muscular spasm (for example bladder or alimentary smooth muscle spasm) is present and where the elevation of cAMP levels may be expected to prevent or alleviate the inflammation and relax muscle.

- 15 Particular uses to which the compounds of the invention may be put include the prophylaxis and treatment of asthma, especially inflamed lung associated with asthma, or in the treatment of inflammatory airway disease, chronic bronchitis, eosinophilic granuloma, psoriasis and other benign and malignant proliferative skin diseases, endotoxic shock, septic
20 shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restonosis and ortherosclerosis.

- 25 Compounds of the invention also suppress neurogenic inflammation through elevation of cAMP in sensory neurones. They are, therefore, analgesic, anti-tussive and anti-hyperalgesic in inflammatory diseases associated with irritation and pain.

- 30 Compounds according to the invention may also elevate cAMP in lymphocytes and thereby suppress unwanted lymphocyte activation in immune-based diseases such as rheumatoid arthritis, ankylosing spondylitis, transplant rejection and graft versus host disease.

Compounds according to the invention have also been found to reduce gastric acid secretion and therefore can be used to treat conditions associated with hypersecretion.

- 5 Compounds of the invention suppress cytokine synthesis by inflammatory cells in response to immune or infectious stimulation. They are, therefore, useful in the treatment of bacterial fungal or viral induced sepsis and septic shock in which cytokines such as tumour necrosis factor (TNF) are key mediators. Also compounds of the invention suppress inflammation
10 and pyrexia due to cytokines and are, therefore, useful in the treatment of inflammation and cytokine-mediated chronic tissue degeneration which occurs in diseases such as rheumatoid or osteo-arthritis.

- 15 Over-production of cytokines such as TNF in bacterial, fungal or viral infections or in diseases such as cancer, leads to cachexia and muscle wasting. Compounds of the invention ameliorate these symptoms with a consequent enhancement of quality of life.

- 20 Compounds of the invention elevate cAMP in certain areas of the brain and thereby counteract depression and memory impairment.

- Compounds of the invention suppress cell proliferation in certain tumour cells and can be used, therefore, to prevent tumour growth and invasion of normal tissues.

25

- For the prophylaxis or treatment of disease the compounds according to the invention may be administered as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one
30 or more pharmaceutically acceptable carriers, excipients or diluents.

- Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration, or a form suitable for administration by inhalation or insufflation.

35

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

20

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

The compounds for formula (1) may be formulated for parenteral administration by injection e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoules or multi dose containers, e.g. glass vials. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

In addition to the formulations described above, the compounds of formula (1) may also be formulated as a depot preparation. Such long acting

formulations may be administered by implantation or by intramuscular injection.

5 For nasal administration or administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.

10

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.

15


The quantity of a compound of the invention required for the prophylaxis or treatment of a particular inflammatory condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around 100ng/kg to 100mg/kg, e.g. around 0.01mg/kg to 40mg/kg body weight for oral or buccal administration, from around 10ng/kg to 50mg/kg body weight for parenteral administration and around 0.05mg to around 1000mg e.g. around 0.5mg to around 1000mg for nasal administration or administration by inhalation or insufflation.

25

The compounds according to the invention may be prepared by the following processes. The symbols Y, R², R³, R⁴, R⁵, R⁶, R⁷ and X, when used in the formulae below are to be understood to represent those groups described above in relation to formula (1) unless otherwise indicated. In the reactions described below it may be necessary to protect reactive functional groups, for example hydroxy, amino, thio, or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice [see, for example, 30 Green, T. W. in "Protective Groups in Organic Synthesis" John Wiley and 35

Sons, 1981.] It may be that deprotection will form the last step in the synthesis of compounds of formula (1).

- Thus according to a further aspect of the invention a compound of formula (1) wherein R^3 is a hydrogen atom or a hydroxyl group and R^6 and R^7 is each a hydrogen atom may be generally prepared by cyclisation of a compound of formula (3):




- [where R^3 is as just defined and R is a carboxylic acid $[-CO_2H]$ group or a reactive derivative thereof, or a nitrile $[-CN]$ or an imine salt] with a bifunctional reagent $W^1R^{5a}W^2$ and, where necessary, a compound $R^{5b}W^3$ [where W^1 , W^2 and W^3 , which may be the same or different, is each a reactive functional group or a protected derivative thereof; and R^{5a} and R^{5b} are components of the group R^5 such that when added together with W^1 , W^2 and W^3 to the group R in compounds of formula (3) the resulting group $-RW^1R^{5a}W^2$ or $-RW^1R^{5a}W^2R^{5b}W^3$ constitutes the group R^5].
- The reaction is particularly suitable for preparing compounds of formula (1) where R^3 is a hydrogen atom and R^5 is a heterocyclic ketone, from the corresponding compound of formula (3) where R^3 is a hydrogen atom.
- Reactive derivatives of carboxylic acids for use in this reaction include acid halides, (e.g. acid chlorides), amides, including thioamides, or esters, including thioesters. Imine salts include for example salts of formula $-C(OAlk)=NH_2^+A^-$ [where Alk is a C_{1-4} alkyl group and A^- is a counterion e.g. a chloride ion].
- In this general reaction the reactive functional groups represented by W^1 , W^2 or W^3 may be any suitable carbon, nitrogen, sulphur or oxygen nucleophiles. Particular examples include simple nucleophiles such as

carbanions [e.g. generated by the coupling of an alkyl group with an organometallic compound], amino, thiol and hydroxyl groups.

- In general, the cyclisation reaction will initially be performed in a solvent,
 5 for example an alcohol, e.g. ethanol at an elevated temperature, e.g. around the reflux temperature, where necessary in the presence of a base or a thiation reagent, e.g. Lawesson's reagent.


- Active derivatives of the acids of formula (3) and other compounds of
 10 formula (3) where R is a nitrile or an imine salt may be prepared from the corresponding acids [where R is $-\text{CO}_2\text{H}$] using conventional procedures for converting carboxylic acids to such compounds, for example as described in the Examples hereinafter.

- 15 Acids of formula (3) where R^3 is a hydrogen atom and R is $-\text{CO}_2\text{H}$ may be prepared by hydrolysing a diester of formula (4)



- 20 where Alk is a C_{1-4} alkyl group, e.g. an ethyl group, with a base, e.g. sodium hydroxide, in a solvent, e.g. dioxane, at an elevated temperature, e.g. the reflux temperature, followed by acidification at an elevated temperature.

- 25 Diesters of formula (4) may be prepared by reacting a diester of formula (5)




with an organometallic reagent.


- Suitable organometallic reagents include Grignard reagents e.g. R^4MgBr , or organolithium reagents, e.g. R^4Li . The Grignard and lithium reagents are either known compounds or may be prepared in a similar manner to that used to synthesise the known compounds.

- The reaction may be performed in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, at a low temperature e.g. around $-70^{\circ}C$ to ambient temperature.

- Intermediates of formula (5) may be prepared by condensing an aldehyde of formula (6)




- with a malonate, e.g. diethylmalonate, if necessary in the presence of catalysts, e.g. piperidine and acetic acid, in an inert solvent, e.g. toluene, at elevated temperature, e.g. the reflux temperature.
- Aldehydes of formula (6) may be prepared by alkylation of a corresponding compound of formula (7)



- using a compound R^2Hal [where Hal is a halogen atom such as a bromine atom] using the reagents and conditions described hereinafter for the alkylation of intermediates of formula (10).

Intermediates of formula (7) are either known compounds or may be prepared from known starting materials by methods analogous to those used for the preparation of the known compounds.

- 5 Intermediates of formula (3) where R^3 is a hydroxyl group may be prepared by reaction of a ketone of formula (8)




- 10 With an organometallic reagent RCH_2COCH_2Z , where Z is a metal atom, for example a lithium atom.

The reaction may be performed in a solvent such as an ether, e.g. a cyclic ether such as tetrahydrofuran, at a low temperature, e.g. around -70°C to

- 15 ambient.

Reagents RCH_2COCH_2Z are either known compounds or may be prepared, preferably *in situ* during the above process, by reaction of a compound $AlkCH_2Z$ [where Alk is an alkyl group such as a n-propyl group] with a compound RCH_2COCH_3 , where necessary in the presence of a base such as an amine e.g. diisopropylamine using the above-mentioned conditions.


- 20 Ketones of formula (8) may be prepared by oxidation of a corresponding alcohol of formula (9):



using an oxidising agent such as manganese dioxides in a solvent such as dichloromethane at ambient temperature.

Alcohols of formula (9) may be prepared by reaction of an aldehyde of formula (6) with an organometallic reagent such as a Grignard reagent R^4MgBr or organolithium compound R^4Li as described above for the preparation of diesters of formula (4)

In another process according to the invention, a compound of formula (1) may be prepared by alkylation of a compound of formula (10):



using a reagent R^2L , where L is a leaving group.


15

Leaving groups represented by L include halogen atoms such as iodine or chlorine or bromine atoms or sulphonyloxy groups such as arylsulphonyloxy groups, e.g. p-toluenesulphonyloxy.

The alkylation reaction may be carried out in the presence of a base, e.g. an inorganic base such as a carbonate, e.g. caesium or potassium carbonate, an alkoxide, e.g. potassium-t-butoxide, or a hydride, e.g. sodium hydride, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide such as dimethylformamide or an ether, e.g. a cyclic ether such as tetrahydrofuran, at ambient temperature or above e.g. around $40^\circ C$ to $50^\circ C$.

Intermediates of formula (10) may be obtained from the corresponding protected compound of formula (11):

30



wherein X^1 is a protected hydroxy, thio or amino group using conventional procedures [see Green, T. W. *ibid*]. Thus, for example, where X^1 is a t-butyldimethylsilyloxy group, the required hydroxyl group may be obtained by treatment of the protected intermediate with tetrabutylammonium fluoride. The protected intermediate of formula (11) may be prepared in an analogous manner to the compounds of formula (1) using the reactions described herein and appropriately protected intermediates.

In yet another process according to the invention, a compound of formula (1) where R^5 is a pyrid-2-one group may be prepared by displacement of a halogen atom from the corresponding 2-halopyridine of formula (1). The reaction may be performed using a base, for example an alkali metal base such as sodium hydroxide, optionally at an elevated temperature, in a solvent such as a glycol, e.g. diethylene glycol. The halopyridine starting materials for this reaction are either known compounds (see for example European Patent Specification No. 626939) or may be prepared by methods similar to those used for the preparation of the known compounds.

Compounds of formula (1) may also be prepared by interconversion of other compounds of formula (1). Thus, for example, a group represented by R^4 in compounds of formula (1) may be substituted in the aryl or heteroaryl portions by any of the groups R^{10} by an appropriate substitution reaction using the corresponding unsubstituted compound of formula (1) and a R^{10} containing nucleophile or electrophile.

In another example of an interconversion process a compound of formula (1) wherein the aryl or heteroaryl group in R^4 contains a $-CH_2NH_2$ substituent may be prepared by reduction of a corresponding compound

wherein R^4 contains a nitrile group, using for example a complex metal hydride such as lithium aluminium hydride in a solvent such as an ether e.g. diethylether.

- 5 In a further example, a compound of formula (1) wherein the aryl or heteroaryl group in R^4 contains an alkanoylamino or alkanoylaminoalkyl substituent may be prepared by acylation of a corresponding compound wherein R^4 contains a $-NH_2$ or alkylamino group by reaction with an acyl halide in the presence of a base, such as a tertiary amine e.g. triethylamine in a solvent such as dichloromethane.

- 15 In yet another example of an interconversion process, compounds of formula (1) wherein R^4 is substituted by an ester $[CO_2Alk^2]$, e.g. an ethanoate, may be prepared by esterification of a corresponding compound wherein R^4 contains a carboxylic acid, using an acid halide, such as an acid chloride, e.g. acetyl chloride, in an alcohol, such as ethanol, at an elevated temperature, such as the reflux temperature.

- 20 Compounds of formula (1) wherein R^4 is substituted by a carboxylic acid may be prepared from the corresponding compound wherein R^4 contains a formyl group, by oxidation with an oxidising agent, e.g. potassium permanganate, in a solvent, such as an alcohol, e.g. tert-butanol, at ambient temperature.

- 25 In a further interconversion reaction, compounds of formula (1) wherein R^4 is substituted by an aminoalkyl group, such as dimethyl-aminomethyl, may be prepared by reductive amination of a corresponding compound wherein R^4 contains a formyl group, using an amine, e.g. dimethylamine, in the presence of a reducing agent, e.g. sodium cyanoborohydride, if necessary
30 in the presence of a catalyst, e.g. ethanolic HCl, in a solvent, such as an alcohol, e.g. methanol, at ambient temperature.

- In another example of an interconversion reaction a compound of formula (1) wherein R^4 is substituted by a formyl group, may be reduced to the
35 corresponding alcohol, e.g. where R^4 contains a hydroxy-methyl group,

using a reducing agent, e.g. sodium borohydride, in a solvent, such as an alcohol, e.g. ethanol, at a temperature from around 20°C to ambient temperature. The resulting alcohol may then be converted to the corresponding alkoxy derivative, e.g. methoxymethyl, by reaction with an alkyl halide or alkyl sulphonate using the methods and reagents described
5 above for the alkylation of intermediates of formula (8).

In a further example of an interconversion process compounds of formula (1) wherein R⁴ contains a carboxamido (-CONHR¹¹) or an aminocarbonyl (-NHCOR¹¹) group may be prepared by reaction of the corresponding
10 compound wherein R⁴ contains a -CO₂H or a -NH₂ group respectively by reaction with a carbamate, such as isobutyl chloroformate or ethyl chloroformate, in the presence of a base, such as an amine, e.g. triethylamine or N-methylmorpholine, in a solvent, such as dichloromethane, or a
15 mixture of solvents, e.g. tetrahydrofuran and dimethylformamide, at a temperature from around -20°C to room temperature.

In a still further interconversion reaction, compounds of formula (1) wherein R⁴ is substituted by a -NHCONHR¹¹ group may be prepared by
20 reacting a corresponding compound wherein R⁴ is substituted by an amino (-NH₂) group, with an isocyanate, e.g. ethyl isocyanate, in a solvent, e.g. dichloromethane, at ambient temperature.

In another example of an interconversion process, compounds of formula (1) wherein R⁷ is an alkyl group, may be prepared by interconversion of a
25 compound of formula (1) where R⁷ is a hydrogen atom by reaction with a compound R⁷L, where L is a leaving group, for example a halogen atom, such as chlorine, in the presence of a base, for example lithium diisopropylamide, in a solvent such as tetrahydrofuran, at low temperature,
30 such as 0°C.

Compounds of formula (1) wherein R³ is an OR⁹ group where R⁹ is an alkyl, alkoxyalkyl, formyl or alkanoyl group, may be prepared in another example of an interconversion process by reaction of a compound of
35 formula (1) where R³ is a -OH group with a compound R⁹L (where R⁹ is

as just defined and L is a leaving group as described above), in a solvent, such a dichloromethane or tetrahydrofuran in the presence of base, for example triethylamine or potassium tert-butoxide, at room temperature.

- 5 In a further interconversion process compounds of formula (1) wherein R⁹ is a carboxamido (-CONHR¹¹) or a thiocarboxamido (-CSNHR¹¹) group, may be prepared by reaction of a compound of formula (1) wherein R³ is a hydroxyl group with an isocyanate R¹¹NCO or an isothiocyanate R¹¹NCS, in a solvent, for example chloroform, in the presence of a base, for
10 example diisopropylethylamine, at ambient temperature. The isocyanate R¹¹NCO and isothiocyanate R¹¹NCS are known compounds or may be prepared in a conventional manner.

- In a further example, a compound of formula (1) wherein R⁹ is a
15 CONR¹¹R¹² group may be prepared by reaction of a compound of formula (1) wherein R⁹ is a CONHR¹¹ group with a reagent R¹²L (where L is a leaving group as described above) in the presence of a base, for example sodium hydride, in a solvent, such as tetrahydrofuran, at low temperature, for example 0°C.

- 20 In another example, an isothiocyanate of formula (1) where R⁹ is -CSNR¹¹R¹² may be prepared by reacting a compound of formula (1) wherein R⁹ is a (-CONR¹¹R¹²) group with a thiation reagent, such as Lawesson's Reagent, in an anhydrous solvent, for example toluene, at
25 elevated temperature, such as the reflux temperature.

- N-oxides of compounds of formula (1) may be prepared for example by oxidation of the corresponding nitrogen base using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid,
30 at an elevated temperature, for example around 70°C to 80°C, or alternatively by reaction with a peracid such as peracetic acid in a solvent, e.g. dichloromethane, at ambient temperature.

- Salts of compounds of formula (1) may be prepared by reaction of a
35 compound of formula (1) with an appropriate acid or base in a suitable

solvent e.g. an organic solvent such as an ether, using conventional procedures.

Where it is desired to obtain a particular enantiomer of a compound of formula (1) this may be produced from a corresponding mixture of enantiomers using any suitable conventional procedure for resolving enantiomers.

Thus for example diastereomeric derivatives, e.g. salts, may be produced by reaction of a mixture of enantiomers of formula (1) e.g. a racemate, and an appropriate chiral compound, e.g. a chiral acid or base. Suitable chiral acids include, for example, tartaric acid and other tartrates such as dibenzoyl tartrates and ditoluoyl tartrates, sulphonates such as camphor sulphonates, mandelic acid and other mandelates and phosphates such as 1,1'-binaphthalene-2,2'-diyl hydrogen phosphate. The diastereomers may then be separated by any convenient means, for example by crystallisation and the desired enantiomer recovered, e.g. by treatment with an acid or base in the instance where the diastereomer is a salt.

In another resolution process a racemate of formula (1) may be separated using chiral High Performance Liquid Chromatography. Alternatively, if desired a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described above.

The following examples illustrate the invention. The following abbreviations are used: DMF - dimethylformamide; THF - tetrahydrofuran; DME - dimethoxyethane; EtOAc - ethyl acetate; Et₂O - diethyl-ether; Et₃N - triethylamine; BuLi - butyllithium; LDA - lithium diisopropylamide; EtOH - ethanol; RT - room temperature.

All ¹Hnmr spectra were obtained at 300MHz unless specified otherwise.

INTERMEDIATE 1

3-Cyclopentyloxy-4-methoxybenzaldehyde

Cs₂CO₃ (214g, 0.66mol) was added to a mixture of 3-hydroxy-4-methoxybenzaldehyde (100g, 0.66mol) and cyclopentyl bromide (98g, 0.66mol) in anhydrous DMF (500ml). The reaction mixture was stirred at RT for 16h then treated with a further portion of cyclopentyl bromide (98g, 0.66mol) and Cs₂CO₃ (214g, 0.66mol). After a further 6h at RT, the mixture was filtered and concentrated *in vacuo*. The residue was dissolved in CH₂Cl₂ (300ml) and washed with NaOH solution (10%; 2x150ml). The organic layer was dried (MgSO₄), concentrated *in vacuo*, and distilled (150°C, 10⁻²mbar) to afford the title compound (130g) as a viscous colourless oil. δ_H (CDCl₃) 1.5-2.0 (8H, br m, CH₂)₄), 3.87 (3H, s, OMe), 4.80 (1H, br m, OCHCH₂), 6.90 (1H, d, J 8.7Hz, ArH *ortho* to OMe), 7.30-7.45 (2H, m, 2xArH *meta* to OMe), and 9.77 (1H, s, ArCHO).

INTERMEDIATE 2

15 Ethyl 3-(3-Cyclopentylloxy-4-methoxyphenyl)-2-ethoxycarbonyl propenoate

A mixture of Intermediate 1 (109.8, 499.1mmol), diethyl malonate (79.96, 499.1mmol), piperidine (2.5ml) and CH₃CO₂H (12ml) in toluene (700ml) was heated to reflux in a Dean-Stark apparatus for 20h. Further portions of diethyl malonate (9.6g, 59.9mmol), piperidine (2.5ml), and CH₃CO₂H (12ml) were added and heating continued as before for 15h. The reaction mixture was concentrated *in vacuo* to afford the title compound (217g) as a brown oil. δ_H (CDCl₃) 1.33 (6H, t, J 7.1Hz, 2xCO₂CH₂Me), 1.5-2.05 (8H, br m, (CH₂)₄), 3.88(3H, s, OMe), 4.30 (2H, q, J 7.1Hz, CO₂CH₂Me), 4.36 (2H, q, J 7.1Hz, CO₂CH₂Me), 4.73 (1H, br m, OCH), 6.85 (1H, d, J 8.1Hz, ArH *ortho* to OMe), 7.0-7.1 (2H, m, 2xArH *meta* to OMe), and 7.63 (1H, s, HC=CCO₂Et).

INTERMEDIATE 3

30 Diethyl 2-[(3-Cyclopentylloxy-4-methoxyphenyl)phenylmethyl]propan-1-3-dioate

Phenylmagnesium bromide (1.0M in THF; 340ml, 340mmol, 1.29eq) was added over 1.5h to a solution of Intermediate 2 (95.6g, 264mmol) in THF (200ml) at -60°C and stirred at this temperature for a further 5h. The reaction mixture was allowed to warm to -20°C, quenched with 10%

aqueous NH_4Cl (200ml), then extracted with EtOAc (3x100ml). The extract was dried (MgSO_4), concentrated *in vacuo*, the residual brown oil dissolved in EtOH and allowed to crystallise overnight to afford the title compound (74.9g) as a white solid. m.p. 97-98°C. δ_{H} (CDCl_3) 1.01 (6H, t, \downarrow 7.1Hz, $\text{CO}_2\text{CH}_2\text{Me}$), 1.05 (3H, t, \downarrow 7.1Hz, $\text{CO}_2\text{CH}_2\text{Me}$), 1.5-2.0 (8H, br m, $(\text{CH}_2)_4$), 3.77 (3H, s, OMe), 3.9-4.1 (4H, m, $2\times\text{CO}_2\text{CH}_2\text{Me}$), 4.26 (1H, d, \downarrow 12.1Hz, CHCHCO_2Et), 4.67 (1H, d, \downarrow 12.1Hz, CHCHCO_2Et), 4.71 (1H, br m, OCH), 6.7-6.85 (3H, m, C_6H_3), and 7.15-7.35 (5H, m, C_6H_5).

10 **INTERMEDIATE 4**

3-(3-Cyclopentyloxy-4-methoxyphenyl)-3-phenylpropanoic acid

A mechanically stirred solution of Intermediate 3 (70.3g, 0.160mol) in NaOH solution (8M; 600ml) and dioxane (600ml) was heated to reflux for 7h. The reaction mixture was cooled, concentrated hydrochloric acid (about 400ml) added dropwise to pH4 and heating carried overnight to give a homogenous solution. The dioxane was removed *in vacuo* and the mixture partitioned between CH_2Cl_2 (500ml) and H_2O (500ml). The organic layer was separated and combined with further CH_2Cl_2 extracts (3x150ml). The extract was dried (MgSO_4) and concentrated *in vacuo* to give the title compound (55g) as a yellow solid. δ_{H} (CDCl_3) 1.5-2.0 (8H, br m, $(\text{CH}_2)_4$), 3.04 (2H, d, \downarrow 7.9Hz, $\text{CHCH}_2\text{CO}_2\text{H}$), 3.80 (3H, s, OMe), 4.45 (1H, t, \downarrow 7.9Hz $\text{CHCH}_2\text{CO}_2\text{H}$), 4.70 (1H, br m, OCH), 6.7-6.8 (3H, m, C_6H_3), and 7.15-7.35 (5H, m, C_6H_5) (N.B. CO_2H not observed).

25 **INTERMEDIATE 5**

3-(3-Cyclopentyloxy-4-methoxyphenyl)-3-phenylpropanoyl chloride

SOCl_2 (14.8ml, 24.1g, 3eq) was added to a solution of Intermediate 4 (23.0g, 67.5mmol) in CH_2Cl_2 (250ml) and then heated to reflux for 6h. The reaction mixture was allowed to stir at RT overnight then concentrated *in vacuo* to afford the title compound (23.7g) as a dark brown oil. δ_{H} (CDCl_3) 1.5-2.0 (8H, br m, $(\text{CH}_2)_4$), 3.62 (2H, d, \downarrow 8.0Hz, CHCH_2COCl), 3.82 (3H, s, OMe), 4.56 (1H, t, \downarrow 8.0Hz, CHCH_2COCl), 4.73 (1H, br m, OCH), 6.7-6.85 (3H, m, C_6H_3), and 7.15-7.4 (5H, m, C_6H_5).

35 **INTERMEDIATE 6**

Ethyl 5-(3-Cyclopentyloxy-4-methoxyphenyl)-3-oxo-5-phenyl-pentanoate

- n-BuLi (1.6M in hexanes; 29.3ml, 46.9mmol, 4.2eq) was added dropwise at -50°C to a solution of potassium ethyl malonate (2.95g, 22.3mmol, 2.1eq) in THF (60ml). The reaction mixture was allowed to warm to -10°C, stirred for 10 min, then recooled to -65°C and treated dropwise with a precooled solution of Intermediate 5 (4.0g, 11.1mmol) in THF (20ml). The reaction mixture was stirred at -65°C for 20 min, then poured into a stirred mixture of Et₂O (100ml) and aqueous HCl (1M; 150ml). After 0.5h, the organic phase was separated and combined with further Et₂O extracts (2x75ml). The extract was dried (MgSO₄), concentrated *in vacuo*, and the residual oil subjected to chromatography (SiO₂; 40% Et₂O-hexane) to afford a colourless oil (3.4g) which crystallised on standing to give the title compound as a white solid. m.p. 56-58°C (EtOH). δ_H (CDCl₃) 1.24 (3H, t, \downarrow 7 Hz, CO₂CH₂Me), 1.5-1.9 (8H, br m, (CH₂)₄), 3.27 (2H, d \downarrow 7.5Hz, CHCH₂CO), 3.33 (2H, s, CH₂CO₂Et), 3.79 (3H, s, OMe), 4.14 (2H, q, \downarrow 7 Hz, CO₂CH₂Me), 4.52 (1H, t, \downarrow 7.5Hz, CHCH₂CO), 4.69 (1H, m, OCH), 6.7-6.8 (3H, m, C₆H₃), and 7.1-7.35 (5H, m, C₆H₅).

EXAMPLE 1

a) **(±)-3-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]-4,5-dihydro-5-isoxazolone**

- A mixture of Intermediate 6 (800mg, 1.95mmol) and hydroxylamine hydrochloride (203mg, 2.91mmol) in EtOH (20ml) was heated to reflux for 4h then left to stand at RT overnight. The reaction mixture was concentrated *in vacuo* and dissolved in water (20ml) containing Et₃N (0.5ml). The supernatant was decanted off and the oily solid washed with water (20ml). Chromatography (SiO₂; CH₂Cl₂ to 5% MeOH/CH₂Cl₂) afforded a pale yellow solid (500mg) which was recrystallised from EtOH (25ml) to afford the title compound (305mg), as pale yellow microneedles m.p. 137-139°C (Found: C, 73.02; H, 6.65; N, 3.55. C₂₃H₂₅NO₄ requires C, 72.80; H, 6.64; N, 3.69%); δ_H (CDCl₃) 1.5-1.95 (8H, br m, (CH₂)₄), 3.0 (2H, s, CH₂CO), 3.20 (2H, d, \downarrow 8.3Hz, CH₂CHPh), 3.81 (3H, s, OMe), 4.18 (1H, t, \downarrow 8.3Hz, CH₂CHPh), 4.71 (1H, br m, OCH), 6.7-6.85 (3H, m, C₆H₃), and 7.2-7.35 (5H, m, C₆H₅).

The following compound was prepared in a manner similar to the compound of Example 1a.

5 b) (±)-3-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]-1-methyl-4,5-dihydro-5-pyrazolone

From Intermediate 6 (750mg, 1.83mmol) and methylhydrazine (101mg, 120μL, 2.2mmol) in EtOH (20ml). Trituration with a mixture of Et₂O (20ml), EtOAc (3ml), and hexane (5ml) gave a solid which was filtered off,
10 washed with cold Et₂O (5ml) and dried *in vacuo* to afford the title compound (485mg) as a white solid m.p. 105-108°C (Found: C, 73.56; H, 7.06; N, 6.98. C₂₄H₂₈N₂O₃ requires C, 73.44; H, 7.19; N, 7.14%); δ_H (CDCl₃) 1.5-1.9 (8H, br m, (CH₂)₄), 2.87 (2H, s, CH₂CO), 3.13 (2H, d, J 8.2Hz, CH₂CHPh), 3.23 (3H, s, NMe), 3.81 (3H, s, OMe), 4.18 (1H, t, J 8.2Hz, CH₂CHPh), 4.7 (1H, br m, OCH), 6.7-6.8 (3H, m, C₆H₃), and 7.15-7.35 (5H, m, C₆H₅).

EXAMPLE 2

20 (+)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]-2-pyridone

A solution of (+)-2-chloro-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine [4.69mg, 1.15mmol; Example 26 of European Patent Specification No. 626939] and sodium hydroxide (2g, 50mmol) in diethylene glycol (10ml) was heated at 170°C for 2h. The reaction
25 mixture was cooled to RT and the resultant brown gel was partitioned between Et₂O (80ml) and water (60ml). The organic layer was washed with saturated brine (50ml), dried (MgSO₄) and evaporated to give a dark brown gum. Chromatography on silica, eluting with 1—>4% methanol in CH₂Cl₂, afforded the title compound as a pale brown gum (40mg). δ_H (CDCl₃) 1.55-1.90 (8H, m, CH₂C), 3.17 (2H, d, J 8Hz, CH₂Py), 3.78 (3H, s, OMe), 4.14 (1H, t, J 8Hz, CHCH₂Py), 4.67 (1H, m, CO), 5.97 (1H, d, J 7Hz, H_a Py), 6.25 (1H, s, H_c Py), 6.68-6.77 (3H, m, Ar H_{d-f}), 7.13-7.29 (6H, m, Ph+Hb).

FORMULATION EXAMPLES

The compounds of the invention may be formulated for pharmaceutical use in a number of forms using any suitable excipients. Thus, for example, for oral use the compounds of the invention such as the compounds of the Examples may be formulated as a solid dosage form, by mixing an appropriate weight of compound (for example 50mg) with maize starch (50-99%w/w), anhydrous colloidal silica (0-10%w/w) and organic or inorganic acid (up to 1%w/w), to fill capsules of an appropriate size, e.g. white opaque hard gelatine capsules size 3. If desired the same mixture may be compressed into tablets.

The activity and selectivity of compounds according to the invention was demonstrated in the following tests. In these tests the abbreviation FMLP represents the peptide N-formyl-met-leu-phe.

Isolated Enzyme

The potency and selectivity of the compounds of the invention was determined using distinct PDE isoenzymes as follows:

- i. PDE I, rabbit heart
- ii. PDE II, rabbit heart
- iii. PDE III, rabbit heart, Jurkat cells
- iv. PDE IV, HL60 cells, rabbit brain, rabbit kidney and human recombinant PDE IV
- v. PDE V, rabbit lung, guinea pig lung

A gene encoding human PDE IV has been cloned from human monocytes (Livi, *et al.*, 1990, *Molecular and Cellular Biology*, 10, 2678). Using similar procedures we have cloned human PDE IV genes from a number of sources including eosinophils, neutrophils, lymphocytes, monocytes, brain and neuronal tissues. These genes have been transfected into yeast using an inducible vector and various recombinant proteins have been expressed which have the biochemical characteristics of PDE IV (Beavo and Reifsnnyder, 1990, *TIPS*, 11, 150). These recombinant enzymes,

particularly the human eosinophil recombinant PDE IV, have been used as the basis of a screen for potent, selective PDE IV inhibitors.

5 The enzymes were purified to isoenzyme homogeneity using standard chromatographic techniques.

Phosphodiesterase activity was assayed as follows. The reaction was conducted in 150 μ l of standard mixture containing (final concentrations): 50mM 2-[[tris(hydroxymethyl)methyl]amino]-1-ethane-sulphonic acid (TES) 10 -NaOH buffer (pH 7.5), 10mM MgCl₂, 0.1 μ M [³H]-cAMP and vehicle or various concentrations of the test compounds. The reaction was initiated by addition of enzyme and conducted at 30°C for between 5 to 30 mins. The reaction was terminated by addition of 50 μ l 2% trifluoroacetic acid containing [¹⁴C]-5'AMP for determining recovery of the product. An aliquot 15 of the sample was then applied to a column of neutral alumina and the [³H]-cAMP eluted with 10ml 0.1 TES-NaOH buffer (pH8). The [³H]-5'-AMP product was eluted with 2ml 2M NaOH into a scintillation vial containing 10ml of scintillation cocktail. Recovery of [³H]-5'AMP was determined using the [¹⁴C]-5'AMP and all assays were conducted in the linear range of 20 the reaction.

Compounds according to the invention such as compounds of the Examples herein cause a concentration-dependent inhibition of recombinant PDE IV at 0.1 - 1000nM with little or no activity against PDE I, 25 II, III or V at concentrations up to 100 μ M.

2. The Elevation of cAMP in Leukocytes

The effect of compounds of the invention on intracellular cAMP was investigated using human neutrophils or guinea pig eosinophils. 30 Human neutrophils were separated from peripheral blood, incubated with dihydrocytochalasin B and the test compound for 10 min and then stimulated with FMLP. Guinea pig eosinophils were harvested by peritoneal lavage of animals previously treated with intra-peritoneal injections of human serum. Eosinophils were separated 35 from the peritoneal exudate and incubated with isoprenaline and test

compound. With both cell types, suspensions were centrifuged at the end of the incubation, the cell pellets were resuspended in buffer and boiled for 10 min prior to measurement of cAMP by specific radioimmunoassay (DuPont).

5

The most potent compounds according to the Examples induced a concentration -dependent elevation of cAMP in neutrophils and/or eosinophils at concentrations of 0.1nM to 1µM.

10 3. **Suppression of Leukocyte Function**

Compounds of the invention were investigated for their effects on superoxide generation, chemotaxis and adhesion of neutrophils and eosinophils. Isolated leukocytes were incubated with dihydrocytochalasin B for superoxide generation only and test compound prior to stimulation with FMLP. The most potent compounds of the Examples caused a concentration-dependent inhibition of superoxide generation, chemotaxis and adhesion at concentrations of 0.1nM to 1µM.


20 Lipopolysaccharide (LPS)-induced synthesis of tumour necrosis factor (TNF) by human peripheral blood monocytes (PBM) is inhibited by compounds of the Examples at concentrations of 0.01nM to 10µM.

25 4. **Adverse Effects**

In general, in our tests, compounds of the invention have had no observed toxic effects when administered to animals at pharmacologically effective doses.

CLAIMS

1. A compound of formula (1):



(1)

wherein

Y is a halogen atom or a group $-OR^1$ where R^1 is an optionally substituted alkyl group;

X is $-O-$, $-S-$ or $-N(R^8)-$, where R^8 is a hydrogen atom or an alkyl group;

R^2 is an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group;

R^3 is a hydrogen or halogen atom or an $-OR^9$ group, where R^9 is a hydrogen atom or an optionally substituted alkyl, alkenyl, alkoxyalkyl, or alkanoyl group, or a formyl, carboxamido or thiocarboxamido group;

R^4 is a group $-(CH_2)_nAr$, where Ar is a monocyclic or bicyclic aryl group optionally containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms and n is zero or an integer 1, 2 or 3;

R^5 is a C_{3-9} carbocyclic ketone optionally containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms;

R^6 is a hydrogen atom or an optionally substituted alkyl group;

R^7 is a hydrogen atom or an optionally substituted alkyl group; and the salts, solvates, hydrates and N-oxides thereof.

2. A compound according to Claim 1, wherein Y is a group $-OR^1$.


3. A compound according to Claim 2, wherein R^1 is an optionally substituted straight or branched C_{1-3} alkyl group.

4. A compound according to Claim 3, wherein R¹ is a -CH₃ group.
5. A compound according to any of Claims 1 to 4, wherein X is -O-.
- 5 6. A compound according to any of Claims 1 to 5, wherein R² is a cyclopentyl group.
7. A compound according to any of Claims 1 to 6, wherein R³, R⁶ and R⁷ is each a hydrogen atom.
- 10 8. A compound according to any of Claims 1 to 7 wherein R⁴ is a group -CH₂Ar or Ar, wherein Ar is a monocyclic aryl group optionally containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms.
- 15 9. A compound according to Claim 8, wherein R⁴ is an optionally substituted pyridyl, phenyl, thienyl or furyl group.
- 20 10. A compound according to any of Claims 1 to 9 where R⁴ is a C₃₋₅ heterocyclic ketone.
- 25 11. A compound according to Claim 10, wherein R⁵ is an optionally substituted pyrrolidone, thiazolidone, piperidone, pyridone, quinolone, isoquinolone, oxazolone, pyrazolone, thiazolone or isoxazolone group.
- 30 12. A compound which is:
(±)-3-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]-4,5-dihydro-5-isoxazolone;
(±)-3-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]-1-methyl-4,5-dihydro-5-pyrazolone;
(±)-3-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]-4,5-dihydro-5-pyrazolone;
(±)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]-2-pyridone; or
- 35

the resolved enantiomers thereof; and the salts, solvates, hydrates and N-oxides thereof.

13. A pharmaceutical composition comprising a compound of formula (1):

5



(1)

wherein

Y is a halogen atom or a group -OR¹ where R¹ is an optionally substituted alkyl group;

10 X is -O-, -S- or -N(R⁸)-, where R⁸ is a hydrogen atom or an alkyl group;

R² is an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group;

15 R³ is a hydrogen or halogen atom or an -OR⁹ group, where R⁹ is a hydrogen atom or an optionally substituted alkyl, alkenyl, alkoxyalkyl, or alkanoyl group, or a formyl, carboxamido or thiocarboxamido group;


20 R⁴ is a group -(CH₂)ₙAr, where Ar is a monocyclic or bicyclic aryl group optionally containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms and n is zero or an integer 1,2 or 3;

R⁵ is a C₃-9carbocyclic ketone optionally containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms;

R⁶ is a hydrogen atom or an optionally substituted alkyl group;

25 R⁷ is a hydrogen atom or an optionally substituted alkyl group; and the salts, solvates, hydrates and N-oxides thereof.

14. A process for the preparation of a compound of formula (1):



wherein

Y is a halogen atom or a group -OR¹ where R¹ is an optionally substituted alkyl group;

5 X is -O-, -S- or -N(R⁸)-, where R⁸ is a hydrogen atom or an alkyl group;

R² is an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group;

10 R³ is a hydrogen or halogen atom or an -OR⁹ group, where R⁹ is a hydrogen atom or an optionally substituted alkyl, alkenyl, alkoxyalkyl, or alkanoyl group, or a formyl, carboxamido or thiocarboxamido group;

15 R⁴ is a group -(CH₂)_nAr, where Ar is a monocyclic or bicyclic aryl group optionally containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms and n is zero or an integer 1,2 or 3;


R⁵ is a C₃₋₉ carbocyclic ketone optionally containing one or more heteroatoms selected from oxygen, sulphur or nitrogen atoms;

R⁶ is a hydrogen atom or an optionally substituted alkyl group;

20 R⁷ is a hydrogen atom or an optionally substituted alkyl group; and the salts, solvates, hydrates and N-oxides thereof;

which comprises in a final step:

a) the cyclisation of a compound of formula (3);




[where R³ is a hydrogen atom or a hydroxyl group and R is a carboxyl acid [-CO₂H] group or a reactive derivative thereof, or a

nitrile [-CN] or an imino salt] to yield a compound of formula (1) wherein R^3 is a hydrogen atom or a hydroxyl group and R^6 and R^7 is each a hydrogen atom; or

5

- b) the alkylation of a compound of formula (8):



10

using a reagent R^2L , where L is a leaving group; or

15

- c) the displacement of a halogen atom from a compound of formula (1) wherein R^5 is a 2-halopyridine group, to yield a corresponding compound of formula (1) wherein R^5 is a pyrid-2-one group.

20

- d) the interconversion of a compound of formula (1) to another compound of formula (1); or
- e) by reaction of a compound of formula (1) with an acid or base to yield a salt of a compound of formula (1); or
- f) by deprotection of a corresponding protected compound of formula (1); or

25

- g) by resolution of a mixture of two enantiomeric forms of a compound of formula (1) to yield one enantiomeric form of a compound of formula (1).

INTERNATIONAL SEARCH REPORT

International Application No

P 94/02783

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D261/12 C07D231/20 C07D213/64 A61K31/42 A61K31/415
A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TETRAHEDRON LETTERS, no. 40, 1979 pages 3797-3800, MARYANOFF B.E. & MC COMSEY D.F. 'Iminium ion cyclizations. Highly stereoselective synthesis of substituted tetrahydroisoquinoline derivatives' see page 3798, intermediates for compounds 6b, 6c --- -/--	1-5,7,8, 11



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

12 April 1995

Date of mailing of the international search report

- 2. 05. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hartrampf, G

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JOURNAL OF ORGANIC CHEMISTRY, vol. 48, no. 25, 1983 pages 5062-5074, MARYANOFF B.E. ET AL. 'Stereochemistry of intramolecular amidoalkylation reactions in the synthesis of polycyclic isoquinoline derivatives' see page 5072, column 1; example 2 see page 5072, column 2, line 69 see page 5073, column 1, line 31 ---	1-5,7,8, 11
X	EP,A,0 130 069 (MC NEILAB, INC.) 2 January 1985 see page 29, line 12 - line 19 ---	1-5,7,8, 11
X	HETEROCYCLES, vol. 23, no. 11, 1985 pages 2907-2911, KANO S. & YUASA Y. 'A diastereoselective synthesis of 7-arylpyrimido[6,1-a]isoquinolines through N-acyliminium ion cyclization' see page 2908; examples 11A, 11B ---	1-5,7,8, 11
P,X	WO,A,94 12461 (PFIZER INC.) 9 June 1994 see claims 1,9-12 ---	1-14
P,X	WO,A,94 14742 (CELLTECH LIMITED) 7 July 1994 see page 5, line 4 - page 6, line 15; claims 1-11,17,18 ---	1-14
Y	JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 7, July 1989 pages 1450-1457, MARIVET M.C. ET AL. 'Inhibition of cyclic adenosine-3',5'-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues' see table II ---	1-14
Y	JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, no. 1, January 1991 pages 291-298, SACCOMANO N.A. ET AL. 'Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(Bicycloalkyloxy)-4-methoxyphenyl]-2-im idazolidinones' see the whole document ---	1-14
Y	WO,A,91 15451 (SMITHKLINE BEECHAM PHARMA GMBH & SMITHKLINE BEECHAM CORPORATION) 17 October 1991 see the whole document ---	1-14
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No
P GB 94/02783

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO,A,92 07567 (SMITHKLINE BEECHAM CORPORATION) 14 May 1992 see the whole document ---	1-14
P,Y	WO,A,94 14800 (CELLTECH LIMITED) 7 July 1994 see the whole document ---	1-14
P,Y	WO,A,94 20455 (CELLTECH LIMITED) 15 September 1994 see the whole document ---	1-14
P,Y	WO,A,94 20446 (CELLTECH LIMITED) 15 September 1994 see the whole document ---	1-14
A	US,A,4 308 278 (SCHNEIDER G. ET AL.) 29 December 1981 see the whole document -----	1-14

INTERNATIONAL SEARCH REPORT

International Application No.
GB 94/02783

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-130069	02-01-85	AU-B- 563990 AU-A- 2977784 CA-A- 1253155 JP-A- 60069082 US-A- 4595688 US-A- 4719216	30-07-87 03-01-85 25-04-89 19-04-85 17-06-86 12-01-88
WO-A-9412461	09-06-94	AU-B- 5539694 FI-A- 935379 HU-A- 65928	22-06-94 03-06-94 28-07-94
WO-A-9414742	07-07-94	AU-B- 5709294 CA-A- 2129039 CN-A- 1092064 CZ-A- 9402034 EP-A- 0626939 FI-A- 943856 GB-A- 2279075 NO-A- 943091	19-07-94 07-07-94 14-09-94 15-12-94 07-12-94 22-08-94 21-12-94 21-10-94
WO-A-9115451	17-10-91	AU-A- 7670991 EP-A- 0523138 JP-T- 6500071 US-A- 5362915	30-10-91 20-01-93 06-01-94 08-11-94
WO-A-9207567	14-05-92	AU-A- 9030691 EP-A- 0557408 JP-T- 6501708	26-05-92 01-09-93 24-02-94
WO-A-9414800	07-07-94	AU-B- 5709394 EP-A- 0626957	19-07-94 07-12-94
WO-A-9420455	15-09-94	AU-B- 6148894 EP-A- 0640070	26-09-94 01-03-95
WO-A-9420446	15-09-94	AU-B- 6148994 EP-A- 0640065	26-09-94 01-03-95
US-A-4308278	29-12-81	AT-B- 374187 CH-A- 642357	26-03-84 13-04-84

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 94/02783

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4308278		DE-A- 2943877	04-06-80
		FR-A, B 2440360	30-05-80
		GB-A, B 2036010	25-06-80
		NL-A- 7907914	06-05-80
